10 pending office actions • 5 clients
| Client (Assignee) | Pending OAs |
|---|---|
| BIOMARIN PHARMACEUTICAL INC. | 3 |
| Inozyme Pharma, Inc. | 2 |
| Yale University | 2 |
| Westfälische Wilhelms-Universität Münster | 2 |
| Rutgers, The State University Of New Jersey | 1 |
| App # | Title | Client | Examiner | Art Unit | Status | Filed |
|---|---|---|---|---|---|---|
| 18612571 | LYOPHILIZED ENPP1 POLYPEPTIDE FORMULATIONS AND USES THEREOF | Inozyme Pharma, Inc. | BOWERS, ERIN M | 1653 | Non-Final OA | Mar 21, 2024 |
| 18529611 | METHODS FOR TREATING LYSOSOMAL STORAGE DISEASES | Rutgers, The State University Of New Jersey | EIX, EMILY FAY | 1653 | Non-Final OA | Dec 05, 2023 |
| 18319821 | Treatment of ENPP1 Deficiency and ABCC6 Deficiency | Inozyme Pharma, Inc. | XIE, XIAOZHEN | 1674 | Non-Final OA | May 18, 2023 |
| 18297228 | LIVER SPECIFIC PRODUCTION OF ENPP1 OR ENPP3 | Yale University | HUMPHRIES, NICHOLAS ADAM | 1631 | Non-Final OA | Apr 07, 2023 |
| 18148888 | COMPOSITIONS AND METHODS FOR TREATING ALLOGRAFT VASCULOPATHY, MOYAMOYA DISEASE, MOYAMOYA SYNDROME AND INTIMAL PROLIFERATION | Westfälische Wilhelms-Universität Münster | SZPERKA, MICHAEL EDWARD | 1641 | Non-Final OA | Dec 30, 2022 |
| 18058712 | COMPOSITIONS AND METHODS FOR INHIBITING VASCULAR SMOOTH MUSCLE CELL PROLIFERATION | Westfälische Wilhelms-Universität Münster | LEE, JAE W | 1656 | Non-Final OA | Nov 23, 2022 |
| 17822245 | TREATMENT OF DISEASES INVOLVING DEFICIENCY OF ENPP1 OR ENPP3 | Yale University | MOLOYE, TITILAYO | 1632 | Non-Final OA | Aug 25, 2022 |
| 17829620 | Lysosomal Targeting Peptides and Uses Thereof | BIOMARIN PHARMACEUTICAL INC. | ALLEN, MARIANNE P | 1647 | Non-Final OA | Jun 01, 2022 |
| 17634034 | Hydrophobic Peptide Salts for Extended Release Compositions | BIOMARIN PHARMACEUTICAL INC. | REYNOLDS, FRED H | 1658 | Non-Final OA | Feb 09, 2022 |
| 17073828 | Variants of C-Type Natriuretic Peptide | BIOMARIN PHARMACEUTICAL INC. | DRISCOLL, LORA E BARNHART | 3991 | Final Rejection | Feb 22, 2021 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial